GlassScriptPhysician profile
Jennifer M Phillips
NPI 1700301272
$15,323.13
in general payments reported to CMS, 2019-2025
28 companies · $1,614 in 2025
The $1,614 reported for 2025 was more than what 91% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,215 · 2022: $3,433 · 2023: $3,364 · 2024: $3,697 · 2025: $1,614.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,530 · Education: $145.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,530.17 |
| Education | $145.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,238.23 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,131.32 | 2021-2025 | Xifaxan, Trulance, Plenvu |
| Janssen Biotech, INC. | $1,852.90 | 2021-2025 | Stelara, Tremfya |
| Takeda Pharmaceuticals U.S.A., INC. | $1,509.39 | 2021-2025 | Entyvio, Gattex, Eohilia |
| Gilead Sciences, INC. | $801.72 | 2021-2025 | |
| Pfizer INC. | $677.20 | 2021-2025 | |
| Celgene Corporation | $637.11 | 2021-2024 | Zeposia |
| Qol Medical, LLC | $452.07 | 2021-2025 | Sucraid, Sucraid |
| Intercept Pharmaceuticals, INC. | $437.68 | 2021-2025 | Ocaliva |
| Amgen INC. | $366.25 | 2021-2023 | Avsola, Amjevita |
| Regeneron Healthcare Solutions, INC. | $364.26 | 2022-2025 | Dupixent |
| Ironwood Pharmaceuticals, INC | $274.67 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $199.99 | 2021-2024 | Dificid |
| Lilly USA, LLC | $197.57 | 2024-2025 | Omvoh |
| Ardelyx, INC. | $176.97 | 2022-2025 | Ibsrela |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $175.75 | 2023-2025 | |
| Redhill Biopharma INC. | $173.84 | 2021-2022 | |
| Braintree Laboratories, INC. | $163.15 | 2021-2023 | Suflave |
| Aimmune Therapeutics, INC. | $93.24 | 2024-2025 | Vowst |
| Celltrion USA INC. | $83.45 | 2024-2025 | Zymfentra, Vegzelma |
| Madrigal Pharmaceuticals | $71.09 | 2025 | Rezdiffra |
| Nestle Healthcare Nutrition INC. | $60.13 | 2021-2023 | |
| E.R. Squibb & Sons, L.L.C. | $48.50 | 2022 | |
| Phathom Pharmaceuticals, INC. | $46.39 | 2024-2025 | Voquezna |
| Organon LLC | $39.66 | 2023-2024 | Renflexis, Hadlima |
| Exact Sciences Corporation | $21.83 | 2024 | |
| Capsovision, INC. | $14.75 | 2024 | Capsocam Plus |
| Echosens North America, INC. | $14.02 | 2024 | Fibroscan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Phillips listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.